

Spinal Procedures – Table 2 Management of anticoagulants and antiplatelet medications prior to following interventional spine procedures

<u>DRUG</u>	<u>WHEN TO STOP</u>			<u>WHEN TO RESTART</u>
	<u>High-Risk Procedures</u>	<u>Intermediate-Risk Procedures</u>	<u>High-Risk Procedures</u>	
Aspirin (ASA) & ASA combinations	Primary prophylaxis: 6 d Secondary prophylaxis: overall risk stratification	Overall risk stratification	No	24 h
Non-steroidal anti-inflammatory drug (NSAIDs)		No	No	24 h
Diclofenac	1 d	No	No	24 h
Ketorolac	1 d	No	No	24 h
Ibuprofen	1 d	No	No	24 h
Etodolac	2 d	No	No	24 h
Indomethacin	2 d	No	No	24 h
Naproxen	4 d	No	No	24 h
Meloxicam	4 d	No	No	24 h
Nabumetone	6 d	No	No	24 h
Oxaprozin	10 d	No	No	24 h
Piroxicam	10 d	No	No	24 h
Phosphodiesterase inhibitors				24 h
Cilostazol	2 d	No	No	24 h
Dipyridamole	2 d	No	No	24 h
ASA combinations	Primary prophylaxis: 6 d Secondary prophylaxis: risk stratification	Overall risk stratification	No	24 h
Anticoagulants				
Coumadin	5 d, normal INR (International Normalized Ratio)	5 d, normal INR	No	6 h
Acenocoumarol	3 d, normal INR	3 d, normal INR	No	24 h
IV heparin	6 h	6 h	6 h	2 h
Subcutaneous heparin BID or TID	24 h	6 h	6 h	2 h (low-risk procedures) 6 – 8 h (intermediate & high-risk procedures)
Low molecular weight heparin (LMWH)				
Enoxaparin (prophylactic)	12 h	12 h	12 h	4 h (low-risk) 12 -24 h (intermediate & high-risk procedures)
Enoxaparin (therapeutic)	24 h	24 h	24 h	4 h (low-risk) 12 -24 h (intermediate & high-risk procedures)
Dalteparin	24 h	24 h	24 h	4 h (low-risk) 12 -24 h (intermediate & high-risk procedures)
Fibrinolytic agents	48 h	48 h	48 h	
Fondaparinux	4 d	4 d	Overall risk stratification	6 h (low-risk) 24 h (intermediate & high-risk procedures)
P2Y12 inhibitors				
Clopidogrel	7 d	7 d	No	12 – 24 h
Prasugrel	7 – 10 d	7- 10 d	No	24 h
Ticagrelor	5 d	5 d	No	24 h
Cangrelor	3 h	3 h	Overall risk stratification	24 h
Non-vitamin K antagonist oral anticoagulants (NOACs)				
Dabigatran	4 d	4 d	Overall risk stratification	24 h
Rivaroxaban	3 d	3 d	Overall risk stratification	24 h
Apixaban	3 d	3 d	Overall risk stratification	24 h
Edoxaban	3 d	3 d	Overall risk stratification	24 h
GP IIb/IIIa inhibitors				
Abciximab	2 – 5 d	2 – 5 d	2 – 5 d	8 – 12 h
Eptifibatide	8 – 24 h	8 – 24 h	8 – 24 h	8 – 12 h
Tirofiban	8 – 24 h	8 – 24 h	8 – 24 h	8 – 12 h